Building Blocks Catalog

284 Thousand compounds in stock

Original and unique

Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

36B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from May 2023

Recent News

  • 22 May 2023   Press Releases

    Enamine Launches a New Chemistry Site in Germany

    Welcome to the latest update from Enamine - we're delighted to share our growth story with you. In our continued pursuit of scientific excellence and global expansion, we've launched a new subsidiary, Enamine Germany GmbH, based in Frankfurt's Höchst Industrial Park. This significant development strengthens our commitment to provide more localized and efficient services in organic synthesis and medicinal chemistry.

  • 27 April 2023   Press Releases

    Nostrum Biodiscovery and ENAMINE Join Forces to Develop a ...

    Barcelona, Spain, and Kyiv, Ukraine, April 27, 2023. Nostrum Biodiscovery, a leading provider of computational drug discovery services, and ENAMINE, a global supplier of chemical building blocks and screening compounds, announced today a groundbreaking collaboration for the co-development of a revolutionary search engine tailored for the REAL Space billion database. This partnership aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts.

    The collaboration will also focus on enhancing High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process. Nostrum Biodiscovery's state-of-the-art AI-enabled screening platform will take center stage in this effort, boasting the capability to evaluate the entire billion compound collection in just hours. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.

    ENAMINE’s expertise in the rapid and reliable provision of compounds will further strengthen the collaboration, ensuring that researchers have timely access to the vast array of molecules in the REAL Space database. This partnership will facilitate the seamless integration of Nostrum Biodiscovery's computational prowess with ENAMINE’s extensive compound collection, directly impacting companies interested in using services offered by both partners and ultimately benefiting the global scientific community and accelerating the path to new drug discoveries.

    [Victor Guallar, CSO Nostrum Biodiscovery] “We see it every day in our projects, using the REAL Space database with our AI/MM hybrid HTVS platform is a game changer in finding molecules. Our joint venture with ENAMINE demonstrates our commitment to integrating cutting-edge technology and high-quality compound collections to provide the pharmaceutical industry with unparalleled access to resources that expedite drug discovery. We believe that this partnership will serve as a catalyst for innovation, inspiring ventures to explore uncharted territories in the quest for novel therapeutics.”

    [Andrey Tarnovskiy, Sales Director, Europe at Enamine] “This year the size of Enamine’s REAL Space has reached tremendous 36 Billion compounds. We are excited to cooperate with Nostrum Biodiscovery to complement the available suite of search tools for REAL Space exploration with brand-new AI-based solution for high-throughput virtual screening and hope that our synergy will allow to facilitate and strengthen the drug discovery efforts of our customers.”

    Read Press Release

  • 19 April 2023   Press Releases

    Enamine and Endogena Therapeutics – a Successful, Multi-Year Drug ...

    Kyiv, Ukraine, April 19, 2023 - Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinicalstage biotech company focused on the development of endogenous regenerative medicines.

    Enamine provides Endogena with its integrated capability in medicinal chemistry to support Endogena’s small molecule drug discovery programs in the fields of hit finding, hit-to-lead and lead optimization.

    The companies have been collaborating under a Full Time Equivalent (FTE) model since 2019. The two discovery partners have been continuing their research collaboration to date, their research relationship not being impacted by the war in Ukraine. This collaboration extension, along with many others and new ones established by Enamine since February 24, 2022, already under the conflict, is a systematic positive trend experienced by the company, that demonstrates the support of its customers and the trust they have in receiving high-quality service backed up by the unparalleled number of diverse building blocks available at Enamine.

    Sven Weiler, Vice President of Medicinal Chemistry at Endogena, commented: “The interaction with colleagues from Enamine has been a smooth one from the start. In addition to the FTE model, it is great to have access to their huge compound collection and be able to flexibly use Enamine’s capacity to its full potential. We value the output and responsiveness of the Enamine team, helping us to achieve our demanding milestones. It is stunning to see how well Enamine has been able to keep pace after February 2022.”

    Michael Bossert, Head of Strategic Alliances at Enamine, added: “After 13 months of the war in the country, we are especially pleased to announce our collaboration with Endogena, a longlasting partner we have been serving during those several years with extensive medicinal chemistry and SAR efforts”.

    Read Press Release

Upcoming events

  • Jun 18-22


    International Summer School on Organic Synthesis "A. Corbella" - ISOS 2023

  • Jun 18-22


  • Jun 1-2


    Journées ChemBioFrance de la Chimiothèque Nationale


Dear Customers, Dear Colleagues, Dear Friends,

The war in our country lasts more than 10 days. We have put on hold most of our operations in Kyiv and ask our customers to wait until this situation is resolved. We thank all of you for your patience. During this time, we have been able to estimate our resources, capabilities, and plan next steps to be done. Now I would like to highlight some of them:

  1. Data. We have already fully transferred all the digital data on safe servers outside Ukraine. Thus, all our databases, all our internal documentation and procedures, and all the confidential information of our clients are secured and now physically located outside of Ukraine. Also, our internal system is not tied to Ukrainian servers and this fact can facilitate the further organization of the manufacturing process outside Ukraine.

  2. Our stock. The entire collection of screening compounds and major building block collection are in Kyiv. Delivery from Kyiv is impossible now. Our EU stock in Riga and US stock in New Jersey operate as usual. Last few days Ukrainian government has made important steps to facilitate logistics inside and outside Ukraine. Therefore, we hope to resume (at least partially) the delivery process in the nearest time and do our best to ensure the gradual replenishment of both the EU and the US stocks with substances from Ukraine. We cannot disclose any details now, but we actively work in this direction.

  3. Synthesis work. We are going to relocate part of the chemists outside of Ukraine to continue at least part of synthetic work mostly for our FTE customers. The new location is in Riga, Latvia. During the last week, we have received many proposals to accept our people in different institutions/universities/companies located in various countries of Europe. After several discussions, we have decided to focus on Riga.

    First, we have a long-time partnership with the Latvian Institute of Organic Chemistry (LIOS) that is ready to provide us a lab space for up to 20 chemists to retain the synthetic work. We would like to thank our Latvian friends and personally Prof. Osvalds Pugovičs, the head of LIOS, for their willingness to support us. Also, the presence of our EU stock and logistic center in Riga can facilitate smooth workflow in this new location.

    The work won’t be so effective and productive as in Kyiv. The EU stock is relatively small and at least in the nearest few weeks, the transfer of reagents and building blocks from Ukraine will be limited. Also, we cannot expand large-scale activities in Riga, and currently, the team of ~15 chemists are the maximum we can transfer to Riga: according to the martial law, men aged 18-60 cannot leave Ukraine. Also, many chemists have been mobilized and take an active part in volunteer movement. Some cannot leave the country for family reasons.

    Nevertheless, this week first Enamine chemists will come to Riga and start preparing for the arrival of the rest of the team.

  4. We also understand that in these circumstances we need some additional labs where we can deploy at least partial work on the building block synthesis and some custom synthesis tasks. We understand that our building blocks are extremely important for our customers and that their production costs should not increase significantly. Taking this into account we are searching for a possibility to purchase or rent some additional site in Europe or Asia. Alternatively, we are looking for a possibility to enter partnerships with other CROs or vendors to resume the synthetic work on their facilities.

We understand our customers wait for concrete decisions from us to plan future works on their programs. In the nearest time, we are going to disclose some further steps for the stabilization of the Enamine operations.

It is an extremely challenging time for us, but Ukraine will stand.

And Enamine will stand as well.

Slava Ukraini!

Andrey Tolmachov